abstract |
(57) [Summary]nThe present invention relates to enhancing the function of anti-tumor antibodies by modulating the activity provided by FcγRIIB. In particular, blocking SHIP activation by FcγRIIB enhances cytotoxicity elicited by therapeutic antibodies in vivo in humans. The invention further provides an antibody, eg, an anti-tumor antibody, having a variant Fc region that results in binding of the antibody to FcγRIIB with reduced affinity. Various transgenic mouse models indicate that inhibitory FcγRIIB molecules are potent modulators of cell injury in vivo. |